• 1.

    Au E, et al. Cancer in kidney transplant recipients. Nat Rev Nephrol 2018; 14:508520. doi: 10.1038/s41581-018-0022-6

  • 2.

    Howell M, et al. Eliciting patient preferences, priorities and trade-offs for outcomes following kidney transplantation: A pilot best-worst scaling survey. BMJ Open 2016; 6:e008163. doi: 10.1136/bmjopen-2015-008163

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 3.

    Lipson EJ, et al. Successful administration of ipilimumab to two kidney transplantation patients with metastatic melanoma. J Clin Oncol 2014;32:e69-e71. doi: 10.1200/JCO.2013.49.2314

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 4.

    Lipson EJ, et al. Tumor regression and allograft rejection after administration of anti-PD-1. N Engl J Med 2016; 374:896898. doi: 10.1056/NEJMc1509268

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 5.

    Murakami N, et al. A multi-center study on safety and efficacy of immune checkpoint inhibitors in cancer patients with kidney transplant. Kidney Int [published online ahead of print December 23, 2020]. doi: 10.1016/j.kint.2020.12.015; https://www.kidney-international.org/article/S0085-2538(20)31534-9/fulltext

    • Search Google Scholar
    • Export Citation
  • 6.

    Abdel-Wahab N, et al. Checkpoint inhibitor therapy for cancer in solid organ transplantation recipients: An institutional experience and a systematic review of the literature. J Immunother Cancer 2019; 7:106. doi: 10.1186/s40425-019-0585-1

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 7.

    Haslam A, Prasad V. Estimation of the percentage of US patients with cancer who are eligible for and respond to checkpoint inhibitor immunotherapy drugs. JAMA Netw Open 2019; 2:e192535. doi: 10.1001/jamanetworkopen.2019.2535

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 8.

    Krishnamoorthy S, et al. CAR-T therapy in solid organ transplant recipients with treatment refractory posttransplant lymphoproliferative disorder. Am J Transplant 2021; 21:809814. doi: 10.1111/ajt.16367

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 9.

    Mamlouk O, et al. Safety and efficacy of CAR T-cell therapy in kidney transplant recipients. Blood [published online ahead of print December 17, 2020]. doi: 10.1182/blood.2020008759; https://ashpublications.org/blood/article/doi/10.1182/blood.2020008759/474741/Safety-and-Efficacyof-CAR-T-Cell-Therapy-in

    • Search Google Scholar
    • Export Citation

Immunotherapy and Novel Cancer Target Therapies in Kidney Transplant Recipients with Cancer

  • 1 Naoka Murakami, MD, PhD, is an associate physician at the Division of Renal Medicine, Brigham and Women's Hospital, and Instructor of Medicine at Harvard Medical School, Boston, MA. Ala Abudayyeh, MD, is Associate Professor at the Division of Internal Medicine, Section of Nephrology, The University of Texas MD Anderson Cancer Center, Houston, TX.
Restricted access

Cancer is a major cause of death in patients with kidney transplants. The incidence of cancer after transplant is 3- to 100-fold higher than that in the general population, and cancer has been shown to be one of the most feared outcomes in patients with kidney transplants (1, 2). However, data on cancer screening and treatment efficacies of novel cancer therapies in patients with kidney transplants are lacking, as these patients have been typically excluded from clinical studies.

Immune checkpoint inhibitors (ICIs) have revolutionized cancer treatment and become standard therapy for many cancers. They work by

Save